Fundamentals and applications of pharmacogenetics for the clinical laboratory

Annals of Clinical and Laboratory Science

Volumn 29, Issue 2, 1999, Pages 140-149

  Linder, Mark W ^a   Valdes Jr , Roland ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; DRUG DISPOSITION; DRUG METABOLISM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LABORATORY; PHARMACOGENETICS; PRIORITY JOURNAL;

HEMATOLOGY; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MEDICAL ONCOLOGY; PHARMACOGENETICS; PSYCHIATRY;

EID: 0032917480     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Schumacher GE. Introduction to therapeutic drug monitoring. In Therapeutic drug monitoring Schumacher GE, Norwalk CT: Appleton & Lang, 1995.
2. Kiyohara C, Hirohata T, Inutsuka S. The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res 1996; 87:18-24.
3. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change the transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991;110:559-65.
4. Nelson DR, Kamataki T, Waxman DJ, Guengerich P, Estabrook RW, Feyereisen R, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA Cell Biol 1993;12:1-51.
5. Daly AK, Brokmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193-201.
6. Dahl M-L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. Ultra-rapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. JPET 1995;274:516-20.
7. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-95.
8. Agundez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995;57:265-9.
9. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Letters 1996;392: 30-4.
10. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209.
11. Linder MW, Prough RA, Valdes R Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 1997;43:254-66.
12. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C. Extremely rapid hydroxylation of debrisoquine: A case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985;7:478-80.
13. Balant-Gorgia AE, Balant LP, Garrone G. High blood concentrations of imipramine or clomipramine and therapeutic failure: A case report study using drug monitoring data. Ther Drug Monit 1989;11:415-20.
14. Brosen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989;36:537-47.
15. Brosen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 1986;30:679-84.
16. Hamelin BA, Turgeon TJ, Vallee F, Belanger PM, Paquet F, LeBel M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996;60:512-21.
17. Goodnick PJ. Pharmacokinetics of second generation antidepressant: fluoxetine. Psychopharm Bull 1991; 27:503-12.
18. Schutz E, Gummert J, Armstron VW, Mohr FW, Oellerich M. Azathioprine pharmacogenetics: the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur J Clin Chem & Clin Biochem 1996;34:199-205.
19. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Ok Park-Hah J, Iven H, Schmiegelow K, Branum E, O'Brien J, Weinshilboum R. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62:60-73.
20. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai H-L, Pui C-H, Relling MV, Evans WE. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14.
21. Doecke CJ, Cosh DG, Callus AS. Standardized initial warfarin treatment: evaluation of initial treatment response and maintenance dose prediction by randomized trial, and risk factors for an excessive warfarin response. Aust NZ J Med 1991;21:319-324.
22. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF. Hydroxylation of warfarin by human cDNA expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992;5:54-9.
23. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
24. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995;5: 389-92.